Cellular resolution
Connect clonal identity, cell state and surface phenotype at single-cell level.
PRECISION IMMUNOTHERAPEUTICS
Targeting the cells
that drive disease.
KeplerBio develops precision biologics designed to selectively eliminate pathogenic immune-cell clones while preserving healthy immunity.
WHY KEPLERBIO
Broad immune suppression treats the system.
We aim to target the disease-driving cells.
In immune-mediated disease, pathogenic lymphocyte populations can persist within otherwise functional immunity. KeplerBio uses high-resolution cellular profiling to distinguish those disease-driving populations and expose target combinations that can be translated into selective therapeutics.
Combinatorial selectivity
Prioritise target pairs that improve separation of pathogenic and healthy cells.
Therapeutic translation
Convert target logic into antibody formats designed for precise cellular engagement.
DISCOVERY PLATFORM
From patient tissue to a therapeutic hypothesis.
A translational workflow that brings together immunogenomics, computational target prioritisation and antibody engineering.
01
Profile
Single-cell multi-omics and immune-receptor profiling of disease tissue.
02
Resolve
Map clonal populations and distinguish disease-driving cellular states.
03
Prioritise
Identify surface-marker combinations with the strongest therapeutic separation.
04
Engineer
Develop biologics that exploit combinatorial recognition for selective targeting.
SCIENCE BEHIND KEPLERBIO
Built from human disease biology, not a theoretical target list.
KeplerBio grew from single-cell immunogenomics studies of refractory coeliac disease, where pathogenic intestinal lymphocyte clones can be resolved directly in patient tissue and linked to distinctive molecular and cell-surface features.
This human-data-first approach provides the biological foundation for identifying target combinations with the potential to distinguish pathogenic clones from healthy immune populations.
PEER-REVIEWED FOUNDATION
Pathogenic clonal lymphocyte biology in refractory coeliac disease
Peer-reviewed work published in Science Translational Medicine in 2025 established a translational framework for identifying and characterising pathogenic immune-cell clones in refractory coeliac disease.
01
Human intestinal disease samples
02
Single-cell and clonal resolution
03
Therapeutic target discovery
LEAD PROGRAM
Refractory coeliac disease and enteropathy-associated T-cell lymphoma.
KeplerBio’s lead program is built around aberrant intestinal lymphocyte populations associated with refractory coeliac disease and progression to enteropathy-associated T-cell lymphoma.
Our therapeutic strategy uses complementary cell-surface features to increase selectivity for pathogenic populations. Detailed target and antibody information is intentionally kept confidential while the program advances.
Human target discovery
Target validation
Antibody discovery
Bispecific preclinical
Lead program status: target validation and antibody development are advancing toward bispecific preclinical testing.
EXPANSION STRATEGY
A rare-disease entry point with a path into broader T-cell pathology.
The same discovery logic can be applied where pathogenic or malignant T-cell clones carry exploitable combinations of surface markers.
01
RCD
Lead indication
02
EATL
Natural extension
03
T-cell lymphoma
Broader oncology
04
Clonal immune disease
Platform potential
COMPANY
Science-led. Translation-focused.
FL
Prof. Fabio Luciani
Founder & Director
Professor of Systems Immunology, UNSW Sydney
Director of Immunogenomics & Functional Genomics Research Strategy, WIMR
His research integrates single-cell genomics, immunogenomics, immune-receptor biology, computational biology and translational immunology to define disease-driving immune-cell states and identify therapeutic opportunities.
KeplerBio was established to translate discoveries in pathogenic immune-cell biology into precision therapeutics.
CONTACT
Building a more selective way to treat immune disease.
We welcome conversations with investors, translational partners and collaborators interested in precision immunotherapeutics.
Email info@keplerbio.com